Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Patheon, a global provider of manufacturing services and contract development to the global pharmaceutical industry, has appointed Mark Kontny as the president of global pharmaceutical development services (PDS) and chief scientific officer.
Subscribe to our email newsletter
Dr Kontny joins Patheon from Abbott Laboratories, where he was divisional vice president of global pharmaceutical and analytical sciences for its global pharmaceutical research and development organisation.
Wes Wheeler, president and CEO of Patheon, said: “Mark has developed a well deserved reputation for combining strong technical abilities with excellent leadership skills. We look forward to him quickly integrating into the Patheon leadership team and helping us drive our PDS business to an even higher performance level.
“Dr Doug Mendenhall, while stepping down as interim president of our PDS business and chief scientific officer roles, will continue with the company on a part-time basis providing advice and assistance in implementing our technology and alliance strategies. I look forward to Dr Mendenhall’s continued counsel as we continue to grow the company.”
Dr Kontny said: “I am delighted to join Path eon and look forward to leading the PDS organisation to provide best in class development services to accelerate customer molecules to market.”